Invitrogen™ CD69 Monoclonal Antibody (FN50), eBioscience™

Beskrivning

Description: The FN50 monoclonal antibody reacts with human CD69, also known as very early activation antigen (VEA). CD69 is approximately 30 kDa and is expressed on the cell-surface as a disulfide-linked dimer. CD69 is rapidly upregulated upon activation and expressed on lymphocytes, monocytes and platelets. Applications Reported: The FN50 antibody has been reported for use in flow cytometric analysis and immunohistochemical staining. Applications Tested: The FN50 antibody has been tested by flow cytometric analysis of resting and 6-hour TPA-activated human normal human peripheral blood cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD69 (AIM, Active Inducer Molecule) is a gp28/34 disulfide bonded homodimer with a molecular weight of 60 kDa under non-reducing conditions. CD69 contains one or two N linked oligosacaride and the molecule is present on activated platelets. In normal peripheral blood a variable percentage of cells express the CD69 antigen, and it is involved in lymphocyte signal transduction. Expression CD69 is induced upon activation of T lymphocytes, and may play a role in proliferation. Furthermore, the protein may act to transmit signals in natural killer cells and platelets. Alternative splicing results in multiple transcript variants of CD69. Diseases associated with CD69 dysfunction include coccidiodomycosis and asthma.